Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Possible clearance of transfusion-acquired nef/LTR-deleted attenuated HIV-1 infection by an elite controller with CCR5 Δ32 heterozygous and HLA-B57 genotype.

Zaunders J, Dyer WB, Churchill M, Munier CML, Cunningham PH, Suzuki K, McBride K, Hey-Nguyen W, Koelsch K, Wang B, Hiener B, Palmer S, Gorry PR, Bailey M, Xu Y, Danta M, Seddiki N, Cooper DA, Saksena NK, Sullivan JS, Riminton S, Learmont J, Kelleher AD.

J Virus Erad. 2019 Apr 1;5(2):73-83.

2.

RNASeq Analysis of Aedes albopictus Mosquito Midguts after Chikungunya Virus Infection.

Vedururu RK, Neave MJ, Tachedjian M, Klein MJ, Gorry PR, Duchemin JB, Paradkar PN.

Viruses. 2019 Jun 4;11(6). pii: E513. doi: 10.3390/v11060513.

3.

Low levels of HIV-1 envelope-mediated fusion are associated with long-term survival of an infected CCR5-/- patient.

Gorry PR, Ahmad F, Mohl J, Alkhatib G.

AIDS. 2018 Oct 23;32(16):2269-2278. doi: 10.1097/QAD.0000000000001953.

PMID:
30005022
4.

Analysis and dissociation of anti-HIV effects of shRNA to CCR5 and the fusion inhibitor C46.

Ledger S, Howe A, Turville S, Aggarwal A, Savkovic B, Ong A, Wolstein O, Boyd M, Millington M, Gorry PR, Murray JM, Symonds G.

J Gene Med. 2018 Feb;20(2-3):e3006. doi: 10.1002/jgm.3006.

PMID:
29552747
5.

Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.

Flynn JK, Ellenberg P, Duncan R, Ellett A, Zhou J, Sterjovski J, Cashin K, Borm K, Gray LR, Lewis M, Jubb B, Westby M, Lee B, Lewin SR, Churchill M, Roche M, Gorry PR.

AIDS Res Hum Retroviruses. 2017 Dec;33(12):1220-1235. doi: 10.1089/AID.2017.0097. Epub 2017 Sep 26.

PMID:
28797170
6.

HIV-1 and SIV Predominantly Use CCR5 Expressed on a Precursor Population to Establish Infection in T Follicular Helper Cells.

Xu Y, Phetsouphanh C, Suzuki K, Aggrawal A, Graff-Dubois S, Roche M, Bailey M, Alcantara S, Cashin K, Sivasubramaniam R, Koelsch KK, Autran B, Harvey R, Gorry PR, Moris A, Cooper DA, Turville S, Kent SJ, Kelleher AD, Zaunders J.

Front Immunol. 2017 Apr 21;8:376. doi: 10.3389/fimmu.2017.00376. eCollection 2017.

7.

Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.

Borm K, Jakobsen MR, Cashin K, Flynn JK, Ellenberg P, Ostergaard L, Lee B, Churchill MJ, Roche M, Gorry PR.

Retrovirology. 2016 Nov 3;13(1):74.

8.

Genotypic Prediction of Co-receptor Tropism of HIV-1 Subtypes A and C.

Riemenschneider M, Cashin KY, Budeus B, Sierra S, Shirvani-Dastgerdi E, Bayanolhagh S, Kaiser R, Gorry PR, Heider D.

Sci Rep. 2016 Apr 29;6:24883. doi: 10.1038/srep24883.

9.

i-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4.

Griffiths K, Dolezal O, Cao B, Nilsson SK, See HB, Pfleger KD, Roche M, Gorry PR, Pow A, Viduka K, Lim K, Lu BG, Chang DH, Murray-Rust T, Kvansakul M, Perugini MA, Dogovski C, Doerflinger M, Zhang Y, Parisi K, Casey JL, Nuttall SD, Foley M.

J Biol Chem. 2016 Jun 10;291(24):12641-57. doi: 10.1074/jbc.M116.721050. Epub 2016 Apr 1.

10.

Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells.

Gray LR, On H, Roberts E, Lu HK, Moso MA, Raison JA, Papaioannou C, Cheng WJ, Ellett AM, Jacobson JC, Purcell DF, Wesselingh SL, Gorry PR, Lewin SR, Churchill MJ.

J Neurovirol. 2016 Aug;22(4):455-63. doi: 10.1007/s13365-015-0413-4. Epub 2016 Jan 4.

PMID:
26727904
11.

T cell therapies-are T memory stem cells the answer?

Flynn JK, Gorry PR.

Ann Transl Med. 2015 Oct;3(17):251. doi: 10.3978/j.issn.2305-5839.2015.08.13.

12.

Molecular Gymnastics: Mechanisms of HIV-1 Resistance to CCR5 Antagonists and Impact on Virus Phenotypes.

Roche M, Borm K, Flynn JK, Lewin SR, Churchill MJ, Gorry PR.

Curr Top Med Chem. 2016;16(10):1091-106. Review.

PMID:
26324043
13.

CNS-specific regulatory elements in brain-derived HIV-1 strains affect responses to latency-reversing agents with implications for cure strategies.

Gray LR, Cowley D, Welsh C, Lu HK, Brew BJ, Lewin SR, Wesselingh SL, Gorry PR, Churchill MJ.

Mol Psychiatry. 2016 Apr;21(4):574-84. doi: 10.1038/mp.2015.111. Epub 2015 Aug 25.

14.

Inhibition of catechol-O-methyl transferase (COMT) by tolcapone restores reductions in microtubule-associated protein 2 (MAP2) and synaptophysin (SYP) following exposure of neuronal cells to neurotropic HIV.

Lee TT, Chana G, Gorry PR, Ellett A, Bousman CA, Churchill MJ, Gray LR, Everall IP.

J Neurovirol. 2015 Oct;21(5):535-43. doi: 10.1007/s13365-015-0354-y. Epub 2015 Jun 3.

15.

Reliable genotypic tropism tests for the major HIV-1 subtypes.

Cashin K, Gray LR, Harvey KL, Perez-Bercoff D, Lee GQ, Sterjovski J, Roche M, Demarest JF, Drummond F, Harrigan PR, Churchill MJ, Gorry PR.

Sci Rep. 2015 Feb 25;5:8543. doi: 10.1038/srep08543.

16.

Designer antigens for elicitation of broadly neutralizing antibodies against HIV.

Kok T, Gaeguta A, Finnie J, Gorry PR, Churchill M, Li P.

Clin Transl Immunology. 2014 Sep 26;3(9):e24. doi: 10.1038/cti.2014.22. eCollection 2014 Sep.

17.

Stem memory T cells (TSCM)-their role in cancer and HIV immunotherapies.

Flynn JK, Gorry PR.

Clin Transl Immunology. 2014 Jul 18;3(7):e20. doi: 10.1038/cti.2014.16. eCollection 2014 Jul. Review.

18.

Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy.

Lu HK, Gray LR, Wightman F, Ellenberg P, Khoury G, Cheng WJ, Mota TM, Wesselingh S, Gorry PR, Cameron PU, Churchill MJ, Lewin SR.

PLoS One. 2014 Nov 19;9(11):e113341. doi: 10.1371/journal.pone.0113341. eCollection 2014.

19.

Differences in coreceptor specificity contribute to alternative tropism of HIV-1 subtype C for CD4(+) T-cell subsets, including stem cell memory T-cells.

Cashin K, Paukovics G, Jakobsen MR, Østergaard L, Churchill MJ, Gorry PR, Flynn JK.

Retrovirology. 2014 Nov 12;11:97. doi: 10.1186/s12977-014-0097-5.

20.
21.

Is the central nervous system a reservoir of HIV-1?

Gray LR, Roche M, Flynn JK, Wesselingh SL, Gorry PR, Churchill MJ.

Curr Opin HIV AIDS. 2014 Nov;9(6):552-8. doi: 10.1097/COH.0000000000000108. Review.

22.

Inhibition of two temporal phases of HIV-1 transfer from primary Langerhans cells to T cells: the role of langerin.

Nasr N, Lai J, Botting RA, Mercier SK, Harman AN, Kim M, Turville S, Center RJ, Domagala T, Gorry PR, Olbourne N, Cunningham AL.

J Immunol. 2014 Sep 1;193(5):2554-64. doi: 10.4049/jimmunol.1400630. Epub 2014 Jul 28.

23.

HIV-1 transcriptional regulation in the central nervous system and implications for HIV cure research.

Churchill MJ, Cowley DJ, Wesselingh SL, Gorry PR, Gray LR.

J Neurovirol. 2015 Jun;21(3):290-300. doi: 10.1007/s13365-014-0271-5. Epub 2014 Jul 25. Review.

24.

Site-selective solid-phase synthesis of a CCR5 sulfopeptide library to interrogate HIV binding and entry.

Liu X, Malins LR, Roche M, Sterjovski J, Duncan R, Garcia ML, Barnes NC, Anderson DA, Stone MJ, Gorry PR, Payne RJ.

ACS Chem Biol. 2014 Sep 19;9(9):2074-81. doi: 10.1021/cb500337r. Epub 2014 Jul 24.

25.

Distinct HIV-1 entry phenotypes are associated with transmission, subtype specificity, and resistance to broadly neutralizing antibodies.

Chikere K, Webb NE, Chou T, Borm K, Sterjovski J, Gorry PR, Lee B.

Retrovirology. 2014 Jun 23;11:48. doi: 10.1186/1742-4690-11-48.

26.

HIV-1 entry and trans-infection of astrocytes involves CD81 vesicles.

Gray LR, Turville SG, Hitchen TL, Cheng WJ, Ellett AM, Salimi H, Roche MJ, Wesselingh SL, Gorry PR, Churchill MJ.

PLoS One. 2014 Feb 28;9(2):e90620. doi: 10.1371/journal.pone.0090620. eCollection 2014.

27.

Quantifying susceptibility of CD4+ stem memory T-cells to infection by laboratory adapted and clinical HIV-1 strains.

Flynn JK, Paukovics G, Cashin K, Borm K, Ellett A, Roche M, Jakobsen MR, Churchill MJ, Gorry PR.

Viruses. 2014 Feb 10;6(2):709-26. doi: 10.3390/v6020709.

28.

HIV-1 envelope-receptor interactions required for macrophage infection and implications for current HIV-1 cure strategies.

Gorry PR, Francella N, Lewin SR, Collman RG.

J Leukoc Biol. 2014 Jan;95(1):71-81. doi: 10.1189/jlb.0713368. Epub 2013 Oct 24. Review.

29.

Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection.

Cashin K, Jakobsen MR, Sterjovski J, Roche M, Ellett A, Flynn JK, Borm K, Gouillou M, Churchill MJ, Gorry PR.

Retrovirology. 2013 Sep 16;10:98. doi: 10.1186/1742-4690-10-98.

30.

Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C Infection.

Jakobsen MR, Cashin K, Roche M, Sterjovski J, Ellett A, Borm K, Flynn J, Erikstrup C, Gouillou M, Gray LR, Saksena NK, Wang B, Purcell DF, Kallestrup P, Zinyama-Gutsire R, Gomo E, Ullum H, Ostergaard L, Lee B, Ramsland PA, Churchill MJ, Gorry PR.

PLoS One. 2013 Jun 18;8(6):e65950. doi: 10.1371/journal.pone.0065950. Print 2013.

31.

The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes.

Gray LR, Tachedjian G, Ellett AM, Roche MJ, Cheng WJ, Guillemin GJ, Brew BJ, Turville SG, Wesselingh SL, Gorry PR, Churchill MJ.

PLoS One. 2013 Apr 16;8(4):e62196. doi: 10.1371/journal.pone.0062196. Print 2013.

32.

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.

Roche M, Salimi H, Duncan R, Wilkinson BL, Chikere K, Moore MS, Webb NE, Zappi H, Sterjovski J, Flynn JK, Ellett A, Gray LR, Lee B, Jubb B, Westby M, Ramsland PA, Lewin SR, Payne RJ, Churchill MJ, Gorry PR.

Retrovirology. 2013 Apr 20;10:43. doi: 10.1186/1742-4690-10-43.

33.

The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets.

Flynn JK, Paukovics G, Moore MS, Ellett A, Gray LR, Duncan R, Salimi H, Jubb B, Westby M, Purcell DF, Lewin SR, Lee B, Churchill MJ, Gorry PR, Roche M.

Virology. 2013 Jul 20;442(1):51-8. doi: 10.1016/j.virol.2013.03.026. Epub 2013 Apr 17.

34.

CoRSeqV3-C: a novel HIV-1 subtype C specific V3 sequence based coreceptor usage prediction algorithm.

Cashin K, Gray LR, Jakobsen MR, Sterjovski J, Churchill MJ, Gorry PR.

Retrovirology. 2013 Feb 27;10:24. doi: 10.1186/1742-4690-10-24.

35.

Affinofile profiling: how efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV.

Chikere K, Chou T, Gorry PR, Lee B.

Virology. 2013 Jan 5;435(1):81-91. doi: 10.1016/j.virol.2012.09.043. Review.

36.

Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5.

Salimi H, Roche M, Webb N, Gray LR, Chikere K, Sterjovski J, Ellett A, Wesselingh SL, Ramsland PA, Lee B, Churchill MJ, Gorry PR.

J Leukoc Biol. 2013 Jan;93(1):113-26. doi: 10.1189/jlb.0612308. Epub 2012 Oct 17.

37.

Reduced basal transcriptional activity of central nervous system-derived HIV type 1 long terminal repeats.

Gray LR, Cowley D, Crespan E, Welsh C, Mackenzie C, Wesselingh SL, Gorry PR, Churchill MJ.

AIDS Res Hum Retroviruses. 2013 Feb;29(2):365-70. doi: 10.1089/AID.2012.0138. Epub 2012 Sep 25.

38.

Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12.

Sterjovski J, Churchill MJ, Ellett A, Wesselingh SL, Ramsland PA, Gorry PR.

Virology. 2012 Oct 25;432(2):394-404. doi: 10.1016/j.virol.2012.06.024. Epub 2012 Jul 19.

39.

A new way of measuring apoptosis by absolute quantitation of inter-nucleosomally fragmented genomic DNA.

Hooker DJ, Mobarok M, Anderson JL, Rajasuriar R, Gray LR, Ellett AM, Lewin SR, Gorry PR, Cherry CL.

Nucleic Acids Res. 2012 Aug;40(15):e113. Epub 2012 Apr 28.

40.

V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc.

Berro R, Klasse PJ, Jakobsen MR, Gorry PR, Moore JP, Sanders RW.

Virology. 2012 Jun 5;427(2):158-65. doi: 10.1016/j.virol.2012.02.006. Epub 2012 Mar 16. Erratum in: Virology. 2012 Jun 20;428(1):76. Jakobsen, Martin R [added]; Gorry, Paul R [added].

41.

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.

Roche M, Jakobsen MR, Ellett A, Salimiseyedabad H, Jubb B, Westby M, Lee B, Lewin SR, Churchill MJ, Gorry PR.

Retrovirology. 2011 Nov 7;8:89. doi: 10.1186/1742-4690-8-89.

42.

Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.

Cashin K, Roche M, Sterjovski J, Ellett A, Gray LR, Cunningham AL, Ramsland PA, Churchill MJ, Gorry PR.

J Virol. 2011 Oct;85(20):10699-709. doi: 10.1128/JVI.05510-11. Epub 2011 Aug 10.

43.

Increased sensitivity to broadly neutralizing antibodies of end-stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge.

Borggren M, Repits J, Sterjovski J, Uchtenhagen H, Churchill MJ, Karlsson A, Albert J, Achour A, Gorry PR, Fenyö EM, Jansson M.

PLoS One. 2011;6(6):e20135. doi: 10.1371/journal.pone.0020135. Epub 2011 Jun 16.

44.
45.

Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1.

Telwatte S, Moore K, Johnson A, Tyssen D, Sterjovski J, Aldunate M, Gorry PR, Ramsland PA, Lewis GR, Paull JR, Sonza S, Tachedjian G.

Antiviral Res. 2011 Jun;90(3):195-9. doi: 10.1016/j.antiviral.2011.03.186. Epub 2011 Apr 1.

46.

HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism.

Roche M, Jakobsen MR, Sterjovski J, Ellett A, Posta F, Lee B, Jubb B, Westby M, Lewin SR, Ramsland PA, Churchill MJ, Gorry PR.

J Virol. 2011 May;85(9):4330-42. doi: 10.1128/JVI.00106-11. Epub 2011 Feb 23.

47.

CD4-binding site alterations in CCR5-using HIV-1 envelopes influencing gp120-CD4 interactions and fusogenicity.

Sterjovski J, Churchill MJ, Roche M, Ellett A, Farrugia W, Wesselingh SL, Cunningham AL, Ramsland PA, Gorry PR.

Virology. 2011 Feb 20;410(2):418-28. doi: 10.1016/j.virol.2010.12.010. Epub 2011 Jan 8.

48.

Coreceptors and HIV-1 pathogenesis.

Gorry PR, Ancuta P.

Curr HIV/AIDS Rep. 2011 Mar;8(1):45-53. doi: 10.1007/s11904-010-0069-x. Review.

PMID:
21188555
49.

CD4 and MHC class 1 down-modulation activities of nef alleles from brain- and lymphoid tissue-derived primary HIV-1 isolates.

Gray LR, Gabuzda D, Cowley D, Ellett A, Chiavaroli L, Wesselingh SL, Churchill MJ, Gorry PR.

J Neurovirol. 2011 Feb;17(1):82-91. doi: 10.1007/s13365-010-0001-6. Epub 2010 Nov 30.

50.

Genetic and functional heterogeneity of CNS-derived tat alleles from patients with HIV-associated dementia.

Cowley D, Gray LR, Wesselingh SL, Gorry PR, Churchill MJ.

J Neurovirol. 2011 Feb;17(1):70-81. doi: 10.1007/s13365-010-0002-5. Epub 2010 Nov 30.

PMID:
21165788

Supplemental Content

Loading ...
Support Center